Five Prime Announces Second Quarter 2017 Results And Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the quarter ending June 30, 2017.

"We continued to make significant progress on our clinical and pre-clinical programs during the quarter,” said Lewis T. "Rusty" Williams, M.D., Ph.D., president and chief executive officer of Five Prime. "We are advancing our large Phase 1a/1b immuno-oncology trial studying cabiralizumab with OPDIVO® in multiple tumor settings.

Back to news